R-Pharm and Flex Databases to Present Poster on Data Empowered Decision Making at DIA 2014 50th Annual Meeting
Flex Databases, a company specializing in software and consulting services for the healthcare industry, has announced that R-Pharm, a Russian pharmaceutical company, will be presenting a poster on data empowered decision making at DIA 2014 50th Annual Meeting in San Diego, US. The poster has been jointly prepared by R-Pharm and Flex Databases and reflects the experience of implementation of the Flex Databases software platform by R-Pharm.
"There were several questions we needed to solve while scaling our activities and growing the number of projects at R-Pharm", says Mikhail Samsonov, Chief Medical Officer at R-Pharm. "How do we keep track of all our projects, regardless of what stage or functional area they belong to? How do we make sure we maintain the quality of work as new people join? And, most importantly, how do we obtain data for decision making, while not spending unreasonably high amount of time to produce and consolidate reports?
"Flex Databases offered answers to all these questions. We now have a platform which provides a project library and a flexible workflow tool, enabling us to obtain real time project status information and guide activities of our employees at each step. The platform is used to manage and implement projects from a variety of functional areas (Chemistry Manufacturing Control, due diligence, clinical development and operations, regulatory and pharmacovigilance). We are keen to share the knowledge we generated as we believe the industry as a whole could benefit from a move to company-wide platforms, as benefits far outweigh the investment needed. Moreover, growing biotech companies and startups could especially benefit using such approach.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.